CA2453993A1 - Method and composition for treatment of cancer - Google Patents

Method and composition for treatment of cancer Download PDF

Info

Publication number
CA2453993A1
CA2453993A1 CA002453993A CA2453993A CA2453993A1 CA 2453993 A1 CA2453993 A1 CA 2453993A1 CA 002453993 A CA002453993 A CA 002453993A CA 2453993 A CA2453993 A CA 2453993A CA 2453993 A1 CA2453993 A1 CA 2453993A1
Authority
CA
Canada
Prior art keywords
oil
composition
lipid
cancer
clofazimine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002453993A
Other languages
English (en)
French (fr)
Inventor
David Lawson Morris
Mohammad Hossein Pourgholami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unisearch Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453993A1 publication Critical patent/CA2453993A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002453993A 2001-07-17 2002-07-16 Method and composition for treatment of cancer Abandoned CA2453993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR6443A AUPR644301A0 (en) 2001-07-17 2001-07-17 Method and composition for treatment of cancer
AUPR6443 2001-07-17
PCT/AU2002/000954 WO2003007957A1 (en) 2001-07-17 2002-07-16 Method and composition for treatment of cancer

Publications (1)

Publication Number Publication Date
CA2453993A1 true CA2453993A1 (en) 2003-01-30

Family

ID=3830401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453993A Abandoned CA2453993A1 (en) 2001-07-17 2002-07-16 Method and composition for treatment of cancer

Country Status (10)

Country Link
US (1) US20040067952A1 (https=)
EP (1) EP1423118A4 (https=)
JP (1) JP2004536857A (https=)
KR (1) KR20040038984A (https=)
CN (1) CN1551771A (https=)
AU (1) AUPR644301A0 (https=)
BR (1) BR0211436A (https=)
CA (1) CA2453993A1 (https=)
MX (1) MXPA04000518A (https=)
WO (1) WO2003007957A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222084B2 (en) * 2004-03-05 2010-04-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAI agents
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
KR20140051555A (ko) * 2012-10-23 2014-05-02 씨지케이바이오 주식회사 전립선암 예방 및 치료용 약학 조성물
CN103360329B (zh) * 2013-07-18 2015-11-18 中国科学院南海海洋研究所 一类吩嗪化合物及其在制备抗肿瘤药物中的应用
CA2997671A1 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
WO2019060409A1 (en) * 2017-09-19 2019-03-28 The Cleveland Clinic Foundation INHIBITION OF CONNEXIN 46 TO TREAT A GLIOBLASTOMA AND OTHER STATES
CN119564691A (zh) * 2024-12-13 2025-03-07 首都医科大学附属北京佑安医院 氯法齐明在制备治疗癌症的药物中的应用
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3658M (fr) * 1964-02-18 1965-11-02 Michel Marie Andre Guerbet Composition huileuse pour l'injection intravasculaire.
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
US5103018A (en) * 1986-08-26 1992-04-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
ZA928419B (en) * 1991-11-29 1994-03-01 Univ Pretoria Pharmaceutical substances or compositions and their use
DE69528103T2 (de) * 1994-04-05 2003-05-15 Universiteit Van Pretoria, Gauteng Verwendung von Riminophenazin zur Behandlung von MDR-Resistenz
US5763443A (en) * 1994-04-05 1998-06-09 Universiteit Van Pretoria MDR resistance treatment and novel pharmaceutically active riminophenazines
DE19843223A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
AUPP332898A0 (en) * 1998-05-04 1998-05-28 Unisearch Limited Pharmaceutical composition

Also Published As

Publication number Publication date
KR20040038984A (ko) 2004-05-08
AUPR644301A0 (en) 2001-08-09
WO2003007957A1 (en) 2003-01-30
US20040067952A1 (en) 2004-04-08
EP1423118A1 (en) 2004-06-02
CN1551771A (zh) 2004-12-01
BR0211436A (pt) 2004-07-13
JP2004536857A (ja) 2004-12-09
MXPA04000518A (es) 2005-03-07
EP1423118A4 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
JP5242877B2 (ja) チオールをベースとする化学保護剤の投与
Konno Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium
RU2292871C2 (ru) Инъецируемые композиции для контролируемой доставки фармакологически активного соединения
US10729669B2 (en) Compositions and methods for treating cancer
JP5096657B2 (ja) シスプラチン耐性癌治療剤
US20040067952A1 (en) Method and composition for treatment of cancer
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
Levine The physiological disposition of hexamethonium and related compounds
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
US20030012825A1 (en) Metallized molecule therapies
CN1204893C (zh) 药物组合物
ES2393184T3 (es) Método para el tratamiento del cáncer y composiciones para su uso en el mismo
Levi et al. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys
US20110046482A1 (en) Methods for reducing toxicities associated with medical procedures employing radiographic contrast agents
JP2001523248A (ja) １，２，４−ベンゾトリアジンオキシド配合物
AU2002318983A1 (en) Mathod and composition for treatment of cancer
Pourgholami et al. Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol
JP7618235B2 (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
KR19990063735A (ko) 1,2,4-벤조트리아진 옥사이드 제제
US20210386877A1 (en) Radiotherapeutic combination therapy for the treatment of cancer
RU2832338C1 (ru) Инъекционный раствор, содержащий п-боронофенилаланин
Turner et al. Localization of 11C-radiopharmaceuticals in the Greene melanoma of hamsters
HK1070280A (en) Method and composition for treatment of cancer
HK40067136A (zh) 含有对二羟硼基苯丙氨酸的注射液剂
EP1477174A1 (en) Radioactive arsenic-containing compounds and their uses in the treatment of tumors

Legal Events

Date Code Title Description
FZDE Discontinued